Rocket Pharmaceuticals has an approved gene therapy and $279m in cash. Can it deliver on both fronts?
Rocket Pharmaceuticals activates KRESLADI treatment centres with $279.4m in cash. See how launch execution and gene therapy trials shape its outlook.
